ZA848369B - Pharmaceutical compositions containing bilobalid for the treatment of neuropathies - Google Patents

Pharmaceutical compositions containing bilobalid for the treatment of neuropathies

Info

Publication number
ZA848369B
ZA848369B ZA848369A ZA848369A ZA848369B ZA 848369 B ZA848369 B ZA 848369B ZA 848369 A ZA848369 A ZA 848369A ZA 848369 A ZA848369 A ZA 848369A ZA 848369 B ZA848369 B ZA 848369B
Authority
ZA
South Africa
Prior art keywords
bilobalid
neuropathies
treatment
pharmaceutical compositions
compositions containing
Prior art date
Application number
ZA848369A
Other languages
English (en)
Inventor
Sham Sunder Chatterjee
Bernard L Gabard
Hermann E W Jaggy
Original Assignee
Schwabe Willmar Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6212873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA848369(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwabe Willmar Gmbh & Co filed Critical Schwabe Willmar Gmbh & Co
Publication of ZA848369B publication Critical patent/ZA848369B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ZA848369A 1983-10-27 1984-10-26 Pharmaceutical compositions containing bilobalid for the treatment of neuropathies ZA848369B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19833338995 DE3338995A1 (de) 1983-10-27 1983-10-27 Bilobalid enthaltende arzneimittel

Publications (1)

Publication Number Publication Date
ZA848369B true ZA848369B (en) 1985-06-26

Family

ID=6212873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA848369A ZA848369B (en) 1983-10-27 1984-10-26 Pharmaceutical compositions containing bilobalid for the treatment of neuropathies

Country Status (8)

Country Link
US (2) US4571407A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0143977B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS60109522A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE119772T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1238280A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE3338995A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE66527B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA848369B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3626128A1 (de) * 1986-08-01 1988-02-04 Mattern Geb Schupmann Claudia Arzneimittel gegen uebelkeit, erbrechen od.dgl.
US5530023A (en) * 1987-10-20 1996-06-25 Korth; Ruth Production of binding sites for PAF, PAF analogues and PAF antagonists in endothelial cells
EP0540767B9 (en) * 1991-11-04 2004-12-22 Korth, Ruth-Maria, Dr. med Treatment and prevention of mental diseases mediated by elevated lyso paf levels with paf antagonists
US5895785A (en) * 1987-10-20 1999-04-20 Ruth Korth Treatment and prevention of disorders mediated by LA-paf or endothelial cells
DE3802895A1 (de) * 1988-02-01 1989-08-10 Koeltringer Peter Kombinationspraeparat zur behandlung von nervenzell- und nervenfasererkrankungen und verletzungen
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
ATE81015T1 (de) * 1988-07-19 1992-10-15 Abraxas Bio Labs Sa Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien.
US5637302A (en) * 1988-09-20 1997-06-10 Indena Spa Extracts of Ginkgo biloba and their methods of preparation
JP2818220B2 (ja) * 1988-11-04 1998-10-30 フロイント産業株式会社 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
DE3840832A1 (de) * 1988-12-03 1990-06-07 Mueller Robert Dr Aeusserlich anzuwendendes praeparat
DE3940092A1 (de) * 1989-12-04 1991-06-06 Schwabe Willmar Gmbh & Co Extrakt aus blaettern von ginkgo biloba, verfahren zu seiner herstellung und den extrakt enthaltende arzneimittel
DE3940094A1 (de) * 1989-12-04 1991-06-06 Montana Ltd Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel
US5158770A (en) * 1989-12-29 1992-10-27 Freund Industrial Co., Ltd. Aqueous solution containing ginkgo leaf extract
IT1238684B (it) * 1990-02-09 1993-09-01 Indena Spa Derivati del bilobalide,loro usi e formulazioni che li contegono
US6001393A (en) * 1990-08-20 1999-12-14 Daoud; Abdulwahid H. Ginkgo biloba extract enhanced bioavailability composition and food products
DE59209823D1 (de) * 1991-12-23 2000-04-20 Schwabe Willmar Gmbh & Co Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen
US5455232A (en) * 1992-02-04 1995-10-03 Piljac; Goran Pharmaceutical preparation based on rhamnolipid
GB9202993D0 (en) * 1992-02-13 1992-03-25 Indena Spa Novel pharmaceutical uses of bilobalide and derivatives thereof and pharmaceutical compositions adapted for such use
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
EP1033994A4 (en) 1997-11-25 2002-04-03 Pharmanex Inc METHOD FOR PRODUCING BIOGINKGO
EP1085886A1 (en) * 1998-06-11 2001-03-28 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Protecting neurons from ischemia
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
WO2001049307A1 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
DE50101673D1 (de) * 2000-08-17 2004-04-15 Medichemie Ag Ettingen Verwendung von extrakten aus ginkgo biloba-blättern zur traumprovokation
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
FR2842425B1 (fr) * 2002-07-16 2005-04-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse
US20050015263A1 (en) * 2001-11-29 2005-01-20 Beal M Flint Use of gingko biloba extracts to promote neuroprotection and reduce weight loss
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
EP1626693A2 (en) * 2003-05-02 2006-02-22 Georgetown University Ginkgo biloba extract as a treatment for therapeutic- induced neurotoxicity
US20060069157A1 (en) * 2004-02-19 2006-03-30 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy
KR100623164B1 (ko) * 2004-07-22 2006-09-19 재단법인서울대학교산학협력재단 뇌신경 보호효과를 갖는 신규한 은행잎 엑스를 정제하는방법 및 이를 함유하는 조성물
US7901675B2 (en) * 2004-10-13 2011-03-08 U.S. Department Of Veterans Affairs Method of using coenzyme Q10 to treat Huntington's disease
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
JP4609890B2 (ja) * 2005-10-03 2011-01-12 株式会社常磐植物化学研究所 抗うつ剤
DE202011108417U1 (de) 2011-11-29 2012-03-01 Ruth-Maria Korth Örtliche und dietätische Kompositionen ohne Etherlipide, Etherphospholipide, Alkylradikale, die geeignet sind für sensible Personen
PT3682870T (pt) 2019-01-15 2023-09-25 Dr Willmar Schwabe Gmbh & Co Kg Processo para a preparação de comprimidos fáceis de tomar com extrato seco de folhas de ginkgo biloba
CN111803487B (zh) * 2019-04-10 2022-12-02 成都百裕制药股份有限公司 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途

Also Published As

Publication number Publication date
DE3486378D1 (de) 1995-04-20
CA1238280A (en) 1988-06-21
JPS60109522A (ja) 1985-06-15
EP0143977A3 (en) 1987-05-13
US4892883A (en) 1990-01-09
EP0143977A2 (de) 1985-06-12
IE842765L (en) 1985-04-27
JPS6241688B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1987-09-04
DE3338995A1 (de) 1985-05-09
DE3338995C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-03-22
EP0143977B1 (de) 1995-03-15
IE66527B1 (en) 1996-01-24
ATE119772T1 (de) 1995-04-15
US4571407A (en) 1986-02-18

Similar Documents

Publication Publication Date Title
ZA848369B (en) Pharmaceutical compositions containing bilobalid for the treatment of neuropathies
GB2188844B (en) Pharmaceutical composition for the treatment of psoriasis
EP0243002A3 (en) Pharmaceutical composition for the treatment of periodontal diseases
DE3070189D1 (en) Medicament, particularly for the treatment of cholera, and pharmaceutical compositions containing it
IL76561A (en) Pharmaceutical compositions containing ifn-ypsilon for the treatment of rheumatic diseases
GB8727099D0 (en) Compositions containing melantonin/homologues
DK542781A (da) Tricycliske cytosinderivater til anvendelse som laegemidler samt fremgangsmaade til fremstilling heraf
IL83775A0 (en) Fumaramide derivatives and pharmaceutical compositions containing them for treating skin diseases
DE3261760D1 (en) Pharmaceutical compositions for the treatment of skin
ZA82361B (en) Pharmaceutical composition for treating diseases of the oral cavity
GB2105992B (en) Pharmaceutical composition for treatment of cardio-vascular diseases
GB2022998B (en) Phermaceutical composition for the treatment of neoplasticand other diseases
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
DE3371515D1 (en) Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them
GB8808598D0 (en) Pharmaceutical compositions for treatment of prophylaxis of skin disorders
DE3272384D1 (en) Medicinal composition for the treatment of certain neuroviroses
ZA814902B (en) Novel thiazol-2-yl-oxamic acid derivatives,their preparation and therapeutic agents containing these compounds
EP0301449A3 (en) Enantiomers of propafenone-containing therapeutic agents
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
PH17582A (en) Pharmaceutical compositions for the treatment of diabetes
GR3004272T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT8249521A0 (it) Composizioni farmaceutiche contenenti idrossicicloesilammine da usare nel trattamento di malattie respiratorie
JO1493B1 (en) Pharmaceutical combination for treating high blood pressure
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
DE3366025D1 (en) Medicine for the treatment of the neoplazic disease